AI-generated summary
The authors systematically reviewed 10 clinical trials of photobiomodulation for oral mucositis in adults with head and neck cancer receiving chemoradiotherapy. They report that prophylactic use was associated with fewer severe cases and lower average mucositis grade, and treatment use was associated with shorter duration of severe mucositis, with reduced pain and better quality of life.
- Participants
- 759
- Studies included
- 10
- Who or what was studied
- Adult patients with head and neck cancer receiving chemoradiotherapy
- Wavelengths
- 850 nm
- Limits stated in the abstract
- The abstract does not describe a risk-of-bias or certainty assessment, and the included studies used different mucositis, pain and quality-of-life scales and laser types.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Background
This systematic review was performed to analyze the therapeutic efficacy of photobiomodulation (PBM) in managing oral mucositis (OM) that appears in this context.
Material And Methods
The search strategy of the systematic review was conducted according to PRISMA guidelines. The eligibility criteria according to PICO process has been defined as follows: Population (P): adult patients with head and neck cancer; Intervention (I): PBM; Comparison (C): placebo group; Outcome (O): pain, oral quality of life (QoL), evolution of the grade OM and pain. The set criteria for inclusion were peer-reviewed articles.
Results
The following database were searched from November 2021 to February 2022, for clinical trials: Pubmed, Scopus and Cochrane. From 296 records, 10 studies were included involving in the systematic review. Data from 759 patients who received chemoradiotherapy were analyzed. These studies used different classifications for oral mucositis (WHO, NCI, RTOF/EORTC), pain (VAS) and quality of life (EORTC QLQ-C30, UW-QOL (v4), FACT-HN). PBM therapy protocol used five different lasers (GaAlAs, InGaAlP, He-Ne, diode laser, red and near-IR LED probe) with wavelengths ranging from 632,8nm to 850nm. Pain evaluation in was based on the visual analogue scale (VAS) mainly. Prophylactic PBM was effective as it reduced the incidence of grades 3-4 and reduced the overall mean grade of OM during the chemoradiotherapy course compared to the control group. On the other hand, when PBM was used for treatment purposes, it decreased the mean duration of OM compared to the placebo arm.
Conclusions
PBM reduced the incidence of more severe grade of OM induced by chemoradiotherapy. Also, PBM therapy reduced the mean duration of severe OM, mean pain scores and subsequently improved QoL. Key words:Oral mucositis, photobiomodulation, low-level laser therapy, chemotherapy, radiotherapy.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 850nm
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Systematic review, Oral mucositis, Visual analogue scale, GRADE, Laser, Low-level laser therapy, Light-emitting diode. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.